Tara Kirkpatrick, MD
Urology · Lincoln, NENPI 1518227958
Payments from drug & device makers
What this record shows
This record is dominated by other: $5,639 of the $7,838 with a category attached, or 71.9%. Angiodynamics, Inc. accounts for 71.9% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $5,842, more than ten times the $519 reported in 2019.
Across 117 payments — averaging $66.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$6K
- AbbVie$429
- Astellas Pharma US Inc$410
- Boston Scientific$169
- Neotract Inc.$137
- Pfizer$101
- plus $952 from 26 others
What the payments were for
- Food & beverage$1,95225%
- Education$2473%
- Other$5,63972%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 1 | $5,639 |
| AbbVie(2 entities) | 28 | $429 |
| Astellas Pharma US Inc | 18 | $410 |
| Boston Scientific | 8 | $169 |
| Neotract Inc. | 4 | $137 |
| Pfizer | 7 | $101 |
| Johnson & Johnson | 7 | $97 |
| Urogen Pharma, Inc. | 3 | $78 |
| Procept Biorobotics Corporation | 2 | $77 |
| Myovant Sciences Inc. | 5 | $76 |
| Dendreon Pharmaceuticals LLC | 4 | $65 |
| Travere Therapeutics, Inc. | 5 | $59 |
| Medtronic | 1 | $54 |
| Bayer | 3 | $51 |
| Isoray, Inc | 1 | $36 |
| Calyxo, Inc. | 1 | $36 |
| Davol Inc. | 1 | $34 |
| Novo Nordisk | 1 | $34 |
| Axonics, Inc. | 1 | $32 |
| KARL Storz Endoscopy-america | 2 | $28 |
| Sun Pharmaceutical Industries Inc. | 2 | $28 |
| Coloplast | 2 | $23 |
| Rochester Medical Corporation | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Blue Earth Diagnostics | 1 | $14 |
| Photocure Inc | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Amgen | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$5,639
How this compares
$7,838 in reported general payments places this provider in the 70th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 47 | $594,547 |
| GemtesaVibegron | 347 | $201,234 |
| MyrbetriqMirabegron | 116 | $62,148 |
| Abiraterone Acetate | 37 | $26,816 |
| Methenamine Hippurate | 250 | $15,476 |
| Estradiol | 133 | $9,939 |
| Trospium Chloride ErTrospium Chloride | 50 | $5,796 |
| Potassium Citrate ErPotassium Citrate | 41 | $5,453 |
| Tamsulosin Hcl | 307 | $3,662 |
| Finasteride | 285 | $2,814 |
| Cefdinir | 45 | $1,517 |
| Trospium Chloride | 26 | $1,236 |
| Trimethoprim | 33 | $1,223 |
| Bethanechol Chloride | 19 | $864 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $410 | $656,695163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 urology providers in Nebraska.
Other urology in Lincoln
- Antonio BeltranLincoln$51K
- Thomas BrushLincoln$15K
- Adam MuesLincoln$14K
- Lance WiebuschLincoln$13K
- David WiltfongLincoln$13K
- Logan McGuffeyLincoln$10K
- Aaron PomajzlLincoln$9K
- Brandon HensleeLincoln$7K
- Andrew LepinskiLincoln$4K
- Jonathan HenningLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.